- Home
- CTXR vs LPCN Comparison
CTXR vs LPCN Comparison
Compare CTXR & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTXR
- LPCN
- Stock Information
- Founded
- CTXR 2007
- LPCN 1997
- Country
- CTXR United States
- LPCN United States
- Employees
- CTXR N/A
- LPCN N/A
- Industry
- CTXR Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- CTXR Health Care
- LPCN Health Care
- Exchange
- CTXR Nasdaq
- LPCN Nasdaq
- Market Cap
- CTXR 28.4M
- LPCN 27.1M
- IPO Year
- CTXR N/A
- LPCN N/A
- Fundamental
- Price
- CTXR $3.30
- LPCN $4.37
- Analyst Decision
- CTXR Strong Buy
- LPCN Strong Buy
- Analyst Count
- CTXR 2
- LPCN 1
- Target Price
- CTXR $54.50
- LPCN $10.00
- AVG Volume (30 Days)
- CTXR 185.5K
- LPCN 34.0K
- Earning Date
- CTXR 02-12-2025
- LPCN 03-06-2025
- Dividend Yield
- CTXR N/A
- LPCN N/A
- EPS Growth
- CTXR N/A
- LPCN N/A
- EPS
- CTXR N/A
- LPCN N/A
- Revenue
- CTXR N/A
- LPCN $7,922,926.00
- Revenue This Year
- CTXR N/A
- LPCN N/A
- Revenue Next Year
- CTXR $216.25
- LPCN N/A
- P/E Ratio
- CTXR N/A
- LPCN N/A
- Revenue Growth
- CTXR N/A
- LPCN N/A
- 52 Week Low
- CTXR $2.44
- LPCN $3.20
- 52 Week High
- CTXR $26.75
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- CTXR 41.54
- LPCN 38.51
- Support Level
- CTXR $3.70
- LPCN $4.48
- Resistance Level
- CTXR $4.43
- LPCN $4.89
- Average True Range (ATR)
- CTXR 0.54
- LPCN 0.35
- MACD
- CTXR 0.06
- LPCN -0.06
- Stochastic Oscillator
- CTXR 6.03
- LPCN 9.60
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.